ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
Mankind Pharma acquires a 70% stake in Armed Cell Therapeutics BV for 48 million euros to enter the cell- and gene-therapy segment. The deal funds a pipeline treating lymphomas and lung cancers using CAR-T therapies developed by the Belgium-incorporated company.
Tap to vote and see what everyone thinks.
Summary by ByteBrief